Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could carob extract help prevent diabetes? new trial seeks answers

NCT ID NCT07379931

Disease control Sponsor: Universidad Católica San Antonio de Murcia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a liquid carob extract can improve blood sugar levels in 70 adults with prediabetes. Participants take the extract or a placebo twice daily for 90 days. Researchers will measure blood glucose and insulin responses to see if the extract helps control blood sugar and may prevent progression to type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carob extract (dietary supplement)
What this could lead to
If it works, this could offer a natural supplement to help manage blood sugar and reduce the risk of developing type 2 diabetes.
What could go wrong
This is a small, early-stage trial with only 70 participants. The supplement may not significantly improve glucose control, and results may not apply to everyone with prediabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects of both sexes aged between 18 and 65. * Diagnosis of prediabetes according to the American Diabetes Association (at least one of the following criteria): * Impaired fasting glucose (100-125 mg/dL) * Glucose intolerance (oral glucose tolerance test with blood glucose between 140-199 mg/dL after 2 hours). * Glycated hemoglobin between 5.7 and 6.4% * Subjects with a body mass index between 20-35 kg/m2. * Stable eating habits: no weight gain or loss of more than 5 kg in the last ten weeks. * Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements. Exclusion Criteria: * Use of medications that may interfere with glucose metabolism. * Subjects with a history of any type of liver or kidney disease. * Alcohol consumption greater than 20 g/day. * History of allergic hypersensitivity or poor tolerance to any component of the products under study. * Participation in another clinical trial in the three months prior to the study. * Unwillingness or inability to comply with clinical trial procedures. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes (insulin resistance, impaired glucose tolerance) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes (insulin resistance, impaired glucose tolerance)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCAM HiTech, Sport & Health Innovation Hub

    Murcia, Murcia, 30107, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.